PRO-Pharmaceuticals,inc. ( ABOUT )

David Platt, Ph.D.
President , Chief Executive Officer,
Chairman of the Board,
Member of the Scientific Advisory Board

David Platt, Ph.D., is the President, Chief Executive Officer and Chairman of the Board of Directors of Pro-Pharmaceuticals Inc. Previous to that he was founder, CEO and Chairman of the Board of Directors of SafeScience Inc. from March 1995 through May 2000 (NASDAQ:SAFS) which achieved a market capitalization of $500,000,000 in July 1999; was the CEO and Chairman of the Board of Directors of IGG from 1992 - 1995, which he founded, took public in 1995 and converted to SafeScience ; and CEO and Chairman of the Board of Directors of Agricultural Glycosystems, Inc. from its inception in 1995 through 2000.

Dr. Platt received a Doctor of Philosophy in Chemistry degree (1988) from The Hebrew University of Jerusalem, Israel. In 1989 Dr. Platt was a research fellow in the Weizmann Institute of Science, Rehovot, Israel, and from 1989 to 1991, Dr. Platt was a research fellow at the Michigan Cancer Foundation, Detroit (re-named Barbara Ann Karmanos Cancer Institute). From 1991 to 1992, Dr. Platt was a research scientist with the Department of Internal Medicine at the University of Michigan, Ann Arbor. Since 1992, Dr. Platt has been actively engaged in the business activity, as described above. Dr. Platt has published peer review articles and many patents, primarily in the field of carbohydrate chemistry.

PAT. NO. Title ----------------------------------------------------------------------------------------------------------

Articles

David Platt and Avraham Raz, "Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin", Journal of the National Cancer Institute, vol. 84, No. 16, (1992), pp. 438-442.